ArticleRenal failure2026
Early 72-h serum creatinine kinetics predict 90-day mortality in hepatorenal syndrome-associated AKI.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatorenal syndrome-associated acute kidney injury (HRS-AKI) carries high short-term mortality. Prognosis is usually based on creatinine-defined AKI stage, but early creatinine trajectories may add information. In this retrospective cohort study (January 2019-September 2024), we included adults with cirrhosis fulfilling contemporary ADQI/ICA-based criteria for HRS-AKI. Using a prespecified 72-h landmark approach, excluding patients who died within the first 72h, we classified serum creatinine kinetics over the first 72 h after diagnosis as increasing or decreasing and evaluated associations with 90-day all-cause mortality after diagnosis. Landmark Cox models adjusted for age, sex, baseline creatinine, Child-Pugh class, and platelet count and tested interaction with AKI stage. Seventy-five patients comprised the landmark cohort (rising
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.